Marginal Zone Lymphoma (MZL)

DBCOND0110322Hemic and Lymphatic DiseasesImmunoproliferative Disorders

Marginal Zone Lymphoma (MZL) is the indication for 3 drugs in DrugBank. It is covered by 3 curated, structured indications.

Also known as
Marginal Lymphoma · Marginal Zone Lymphoma · Marginal Zone Lymphomas · Lymphoma, Marginal Zone · MZL
Classified under
Indicated drugs

Resolves to

Vocabularies
SNOMED CT103683000MedDRA10076596UMLSC1367654

What you can answer from here — as of November 02, 2026

3Indicated drugsWith each drug's targets and mechanism
Listed above
3Structured indicationsPopulation, line of therapy, route and combination as fields, not prose
Sign in
357Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4Drugs reporting it as an adverse effectWith incidence where the label states it
Sign in

Which approved drugs for Marginal Zone Lymphoma (MZL) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In